New Market Research Report: Global Atopic Dermatitis Drugs Market 2017-2021

Fast Market Research announces the availability of the new TechNavio report, "Global Atopic Dermatitis Drugs Market 2017-2021", on their comprehensive research portal

Logo

Boston, MA -- (SBWire) -- 03/27/2017 --Atopic dermatitis is a common, chronic, relapsing, inflammatory disease that primarily affects young children. Atopy refers to an inherited tendency to produce IgE antibodies, whereas, dermatitis means inflammation of the skin. Atopic dermatitis is associated with asthma, inhalant allergies (hay fever), and chronic dermatitis. In this condition, the skin becomes extremely itchy and inflamed, which causes redness, cracking, weeping, swelling, vesicle formation, crushing, and scaling. Atopic dermatitis is very common worldwide, and its prevalence rate is increasing. The data estimates suggest that nearly 60% of the patients develop symptoms in the first year of life, and 88%-92% develop symptoms before the age of five.

Technavio's analysts forecast the global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global atopic dermatitis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.

Get More Details on this Report and a Full Table of Contents at Global Atopic Dermatitis Drugs Market 2017-2021

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-LEO Pharma
-Mylan
-Valeant
-Bayer HealthCare
-Encore Dermatology

Market driver

-Growing prevalence of food allergies exacerbating atopic dermatitis
-For a full, detailed list, view our report

Market challenge

-Poor patient adherence due to inadequate information on drug usage
-For a full, detailed list, view our report

Market trend

-Increasing M&A leading to market consolidation
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: LEO Pharma, Mylan, Valeant, Bayer HealthCare, Encore Dermatology

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Atopic Dermatitis Global Clinical Trials Review, H2, 2016
-Atopic Dermatitis Global Clinical Trials Review, H1, 2016
-Dermatitis Global Clinical Trials Review, H1, 2016
-Dermatitis Global Clinical Trials Review, H2, 2016
-Contact Dermatitis Global Clinical Trials Review, H1, 2016

Media Relations Contact

Bill Thompson
Director of Marketing
Fast Market Research, Inc.
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/783962